# Rituximab and ABVD for Hodgkin's Patients

> **NCT00504504** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 85 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Adriamycin
- **DRUG:** Bleomycin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine (DTIC)

## Key facts

- **NCT ID:** NCT00504504
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2013-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00504504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00504504, "Rituximab and ABVD for Hodgkin's Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00504504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*